モリヤ　タクヤ   Takuya Moriya   森谷　卓也    所属   川崎医科大学  医学部    職種   学長付特任教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
掲載誌名	正式名：Histopathology 略　 称：Histopathology ISSNコード：13652559/03090167
掲載区分	国外
巻・号・頁	pp.1111-1129
国際共著	国際共著
著者・共著者	Veerle Bossuyt, Elena Provenzano, W Fraser Symmans, Fleur Webster, Kimberly H Allison, Chau Dang, Helenice Gobbi, Janina Kulka, Sunil R Lakhani, Takuya Moriya, Cecily M Quinn, Anna Sapino, Stuart Schnitt, D Mark Sibbering, Elzbieta Slodkowska, Wentao Yang, Puay Hoon Tan, Ian Ellis
発行年月	2024/06
概要	AIMS:The International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter-)national pathology and cancer organisations, is an initiative aimed at providing a unified international approach to reporting cancer. ICCR recently published new data sets for the reporting of invasive breast carcinoma, surgically removed lymph nodes for breast tumours and ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions. The data set in this paper addresses the neoadjuvant setting. The aim is to promote high-quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment that can be used for subsequent management decisions for each patient.METHODS:The ICCR convened expert panels of breast pathologists with a representative surgeon and oncologist to critically review and discuss current evidence. Feedback from the international public consultation was critical in the development of this data set.RESULTS:The expert panel concluded that a dedicated data set was required for reporting of breast specimens post-neoadjuvant therapy with inclusion of data elements specific to the neoadjuvant setting as core or non-core elements. This data set proposes a practical approach for handling and reporting breast resection specimens following neoadjuvant therapy. The comments for each data element clarify terminology, discuss available evidence and highlight areas with limited evidence that need further study. This data set overlaps with, and should be used in conjunction with, the data sets for the reporting of invasive breast carcinoma and surgically removed lymph nodes from patients with breast tumours, as appropriate. Key issues specific to the neoadjuvant setting are included in this paper. The entire data set is freely available on the ICCR website.CONCLUSIONS:High-quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment are critical for subsequent management de
DOI	10.1111/his.15165
PMID	38443320